Previous close | 69.39 |
Open | 67.57 |
Bid | 66.75 x 200 |
Ask | 71.25 x 100 |
Day's range | 69.39 - 69.39 |
52-week range | 65.91 - 100.59 |
Volume | |
Avg. volume | 31,208 |
Market cap | 248.995M |
Beta (5Y monthly) | 0.13 |
PE ratio (TTM) | 15.42 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.20 (1.72%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management’s beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amo
SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this re
SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands,